Safety and Effectiveness of Lisdexamfetamine Dimesylate in Paediatric Attention-Deficit/Hyperactivity Disorder Assessed by Physicians and School Teachers: A Post-marketing Surveillance Study

INTRODUCTION: Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug approved for the treatment of paediatric attention-deficit/hyperactivity disorder (ADHD) in Japan. This multicentre, prospective, post-marketing surveillance study evaluated real-world safety and effectiveness of LDX in children and adolescents with ADHD in Japan. METHODS: Patients aged 6 to < 18 years initiating LDX between April 2021 and September 2023 were enrolled across 24 medical institutions in Japan. Safety was assessed over 24 weeks by monitoring adverse drug reactions (ADRs), including dependence/abuse events. Effectiveness was evaluated by physicians and school teachers at baseline, and weeks 12 and 24 using the Japanese ADHD rating scale IV (ADHD-RS-IV) questionnaire. RESULTS: Of the 88 enrolled patients, 73 were included in the safety analysis and 57 in the effectiveness analysis. The mean (standard deviation [SD]) age was 10.4 (2.6) years; 79.5% were male and 20.5% were female. Most patients (90.4%) had received prior ADHD treatment. LDX was initiated at a mean (SD) dose of 26.8 (4.7) mg, with 72.6% continuing treatment at week 24. ADRs occurred in 30.14% of patients; the most common (in ≥ 2 patients) were decreased appetite (17.81%), weight decrease (4.11%), and aggression, insomnia, irritability, middle insomnia, and abdominal pain (each 2.74%). One serious ADR (suicide attempt with methylphenidate overdose, also considered a dependence/abuse event) was reported; LDX was discontinued and the patient recovered the following day. No other dependence/abuse events were reported. Physician- and teacher-rated ADHD-RS-IV total scores improved significantly from baseline: mean (SD) changes were - 10.1 (8.0; p < 0.0001) at week 12 and - 9.7 (8.5; p < 0.0001) at week 24 for physician-rated scores, and - 4.9 (8.5; p < 0.001) at week 12 and - 5.1 (9.7; p < 0.01) at week 24 for teacher-rated scores. CONCLUSIONS: Findings from this post-marketing surveillance study of LDX in paediatric patients with ADHD in Japan were consistent with its established safety profile. Patients' ADHD symptoms improved according to both physician and teacher assessments. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (identifier UMIN000046038).

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s12325-026-03837-4
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety and Effectiveness of Lisdexamfetamine Dimesylate in Paediatric Attention-Deficit/Hyperactivity Disorder Assessed by Physicians and School Teachers: A Post-marketing Surveillance Study

Kouji Yamashita, Takashi Okada, Kazuhiko Saito, Hiroyuki Ida
1 links
Advances in Therapy
Attention Deficit Hyperactivity Disorder
article

Safety and Effectiveness of Lisdexamfetamine Dimesylate in Paediatric Attention-Deficit/Hyperactivity Disorder Assessed by Physicians and School Teachers: A Post-marketing Surveillance Study

Kouji Yamashita, Takashi Okada, Kazuhiko Saito, Hiroyuki Ida
article en

Abstract

INTRODUCTION: Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug approved for the treatment of paediatric attention-deficit/hyperactivity disorder (ADHD) in Japan. This multicentre, prospective, post-marketing surveillance study evaluated real-world safety and effectiveness of LDX in children and adolescents with ADHD in Japan. METHODS: Patients aged 6 to < 18 years initiating LDX between April 2021 and September 2023 were enrolled across 24 medical institutions in Japan. Safety was assessed over 24 weeks by monitoring adverse drug reactions (ADRs), including dependence/abuse events. Effectiveness was evaluated by physicians and school teachers at baseline, and weeks 12 and 24 using the Japanese ADHD rating scale IV (ADHD-RS-IV) questionnaire. RESULTS: Of the 88 enrolled patients, 73 were included in the safety analysis and 57 in the effectiveness analysis. The mean (standard deviation [SD]) age was 10.4 (2.6) years; 79.5% were male and 20.5% were female. Most patients (90.4%) had received prior ADHD treatment. LDX was initiated at a mean (SD) dose of 26.8 (4.7) mg, with 72.6% continuing treatment at week 24. ADRs occurred in 30.14% of patients; the most common (in ≥ 2 patients) were decreased appetite (17.81%), weight decrease (4.11%), and aggression, insomnia, irritability, middle insomnia, and abdominal pain (each 2.74%). One serious ADR (suicide attempt with methylphenidate overdose, also considered a dependence/abuse event) was reported; LDX was discontinued and the patient recovered the following day. No other dependence/abuse events were reported. Physician- and teacher-rated ADHD-RS-IV total scores improved significantly from baseline: mean (SD) changes were - 10.1 (8.0; p < 0.0001) at week 12 and - 9.7 (8.5; p < 0.0001) at week 24 for physician-rated scores, and - 4.9 (8.5; p < 0.001) at week 12 and - 5.1 (9.7; p < 0.01) at week 24 for teacher-rated scores. CONCLUSIONS: Findings from this post-marketing surveillance study of LDX in paediatric patients with ADHD in Japan were consistent with its established safety profile. Patients' ADHD symptoms improved according to both physician and teacher assessments. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (identifier UMIN000046038).

Advances in Therapy
Imperial Gift Foundation Boshi-Aiiku-Kai (JP), Takeda (Japan) (JP), Nara Medical University (JP)
Takeda Pharmaceutical Company, Shionogi
Good health and well-being
Attention Deficit Hyperactivity Disorder
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon